Adefovir Dipivoxil Plus Chinese Medicine in HBeAg-Positive Chronic Hepatitis B Patients: A Randomized Controlled 48-Week Trial
Xiao-ke Li,Ming-xiang Zhang,Feng-zhen Shao,Da-qiao Zhou,Jing-dong Xue,Tie-jun Liu,Xiao-ling Chi,Bing-jiu Lu,Xian-bo Wang,Qin Li,Jun Li,De-wen Mao,Hua-sheng Yang,Hong-zhi Yang,Wen-xia Zhao,Yong Li,Guo-liang Zhang,Yi-ming Zhao,Jian-dong Zou,Meng-yang Liu,Ke-ke Zhang,Xian-zhao Yang,Da-nan Gan,Ying Li,Peng Zhang,Zhi-guo Li,Shuo Li,Yong-an Ye
DOI: https://doi.org/10.1007/s11655-020-3250-0
2020-01-01
Abstract:Objective To evaluate the effects of a 48-week course of adefovir dipivoxil (ADV) plus Chinese medicine (CM) therapy, namely Tiaogan Jianpi Hexue ((sic)& x809d;& x813e;(sic)& x8840;) and Tiaogan Jiedu Huashi ((sic)& x809d;(sic)& x6bd2;(sic)& x6e7f;) fomulae, in hepatitis B e antigen (HBeAg)-positive Chinese patients. Methods A total of 605 HBeAg-positive Chinese CHB patients were screened and 590 eligible participants were randomly assigned to 2 groups in 1:1 ratio including experimental group (EG, received ADV plus CM) and control group (CG, received ADV plus CM-placebo) for 48 weeks. The major study outcomes were the rates of HBeAg and HBV-DNA loss on week 12, 24, 36, 48, respectively. Secondary endpoints including liver functions (enzymes and bilirubin readings) were evaluated every 4 weeks at the beginning of week 24, 36, and 48. Routine blood, urine, and stool analyses in addition to electrocardiogram and abdominal B scan were monitored as safety evaluations. Adverse events (AEs) were documented. Results The combination therapy demonstrated superior HBeAg loss at 48 weeks, without additional AEs. The full analysis population was 560 and 280 in each group. In the EG, population achieved HBeAg loss on week 12, 24, 36, and 48 were 25 (8.90%), 34 (12.14%), 52 (18.57%), and 83 (29.64%), respectively; the equivalent numbers in the CG were 20 (7.14%), 41 (14.64%), 54 (19.29%), and 50 (17.86%), respectively. There was a statistically significant difference between these group values on week 48 (P<0.01). No additional AEs were found in EG. Subgroup analysis suggested different outcomes among treatment patterns. Conclusion Combination of CM and ADV therapy demonstrated superior HBeAg clearance compared with ADV monotherapy. The finding indicates that this combination therapy may provide an improved therapeutic effect and safety profile (ChiCTR-TRC-11001263).